First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

FDA approves obinutuzumab for idiopathic nephrotic syndrome, first new treatment in 70 years

The FDA has approved Roche's obinutuzumab (Gazyva), an anti-CD20 agent, for treating idiopathic nephrotic syndrome in patients as young as 2 years old. This marks the first new drug approval for this kidney condition in seven decades.